By studying fifty COVID-19 patients, researchers in France identified a unique signature - a combination of deficiency in a response of a particular interferon, as well as exacerbated inflammation - in the most critically ill. They propose this signature, which may be a hallmark of severe COVID-19, provides a rationale for therapeutic approaches that combine interferon supplementation with neutralization of inflammatory signaling.
COVID-19 is characterized by distinct patterns of disease progression depending on the patient, which implies patients exhibit different immune responses to the SARS-Cov-2 virus. So far, studies suggest some 5-10% of patients progress to severe or critical disease. However, little is known about the immunological features involved in COVID-19 severity.
To help to fill this gap, the researchers analyzed immune cells of COVID-19 patients with symptoms ranging from mild to critical. The critical patients exhibited a distinctive dual signature involving a deficiency in responses of type I interferons, proteins that help fight viral infections, as well as exacerbated proinflammatory signaling.
While recent work to investigate the role of interferon signaling in COVID-19 patients has shown that local interferon signaling may be important to mitigate disease progression, the results of this dtudy suggest broader production of interferons may in fact be beneficial.
The work of these studies collectively reinforces a growing hypothesis that the location, timing, and duration of interferon exposure are critical parameters underlying the success of therapeutics for SARS-CoV-2 infections. The authors. also suggest severely ill COVID-19 patients could be treated with a combined approach focused on interferon administration and adapted anti-inflammatory therapies, "a hypothesis worth cautious testing," they say.
https://science.sciencemag.org/content/early/2020/07/10/science.abc6027
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fimpaired-type-i&filter=22
Severe COVID-19 patients had impaired type I interferon activity and inflammatory responses
- 1,412 views
- Added
Edited
Latest News
Human skeletal muscle aging…
By newseditor
Posted 13 May
Disruption of organellar co…
By newseditor
Posted 13 May
Functional heterogeneity of…
By newseditor
Posted 13 May
Gut bacteria produced compo…
By newseditor
Posted 13 May
Role of ECM in brain memory
By newseditor
Posted 13 May
Other Top Stories
RNA editing and cancer
Read more
Modulating miRNA's to control tumorigeneis
Read more
A mutated gene found in families with multiple tumors, including ca…
Read more
Long noncoding RNA, HOTAIR promotes prostate cancer
Read more
Molecular mechanism of chemokine receptor mediated hapatic cancer
Read more
Protocols
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Parasympathetic neurons der…
By newseditor
Posted 07 May
Non-invasive measurements o…
By newseditor
Posted 05 May
Publications
Human skeletal muscle aging…
By newseditor
Posted 13 May
Accumulation of APP C-termi…
By newseditor
Posted 13 May
Pharmacological induction o…
By newseditor
Posted 13 May
The Effect of Glycine and N…
By newseditor
Posted 13 May
Diindoles produced from com…
By newseditor
Posted 13 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar